SG11201707527YA - Inhibitors of hepatitis c virus polymerase - Google Patents
Inhibitors of hepatitis c virus polymeraseInfo
- Publication number
- SG11201707527YA SG11201707527YA SG11201707527YA SG11201707527YA SG11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA
- Authority
- SG
- Singapore
- Prior art keywords
- hepatitis
- inhibitors
- virus polymerase
- polymerase
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562136857P | 2015-03-23 | 2015-03-23 | |
PCT/US2016/023664 WO2016154241A1 (en) | 2015-03-23 | 2016-03-23 | Inhibitors of hepatitis c virus polymerase |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201707527YA true SG11201707527YA (en) | 2017-10-30 |
Family
ID=55759915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201707527YA SG11201707527YA (en) | 2015-03-23 | 2016-03-23 | Inhibitors of hepatitis c virus polymerase |
Country Status (19)
Country | Link |
---|---|
US (2) | US10464914B2 (en) |
EP (1) | EP3274340B1 (en) |
JP (1) | JP6741747B2 (en) |
KR (1) | KR20170137113A (en) |
CN (1) | CN107567442B (en) |
AU (1) | AU2016235246B2 (en) |
CA (1) | CA2979555C (en) |
DK (1) | DK3274340T3 (en) |
EA (1) | EA033622B1 (en) |
ES (1) | ES2748974T3 (en) |
HK (2) | HK1243703A1 (en) |
IL (1) | IL254243B (en) |
MX (1) | MX2017012238A (en) |
NZ (1) | NZ735093A (en) |
PH (1) | PH12017501687A1 (en) |
PL (1) | PL3274340T3 (en) |
SG (1) | SG11201707527YA (en) |
TW (1) | TWI731854B (en) |
WO (1) | WO2016154241A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI731854B (en) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Inhibitors of hepatitis c virus polymerase |
CA3096916A1 (en) * | 2018-05-09 | 2019-11-14 | Cocrystal Pharma, Inc. | Combination therapy for the treatment of hepatitis c virus |
CN112745216A (en) * | 2019-10-30 | 2021-05-04 | 常州锐博生物科技有限公司 | Preparation method of methyl 4-bromomethylbenzoate and derivatives thereof |
CN114181187A (en) * | 2021-11-24 | 2022-03-15 | 上海应用技术大学 | Preparation method of 4-methanesulfonamido butyramide compound |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ288897A3 (en) | 1995-03-20 | 1998-02-18 | Eli Lilly And Company | In position 5-substituted 3-(1,2,3,6-tetrahydropyridin-4-yl)indole and 3-(piperidin-4-yl)indole, as well as pharmaceutical composition containing thereof |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
CA2449999C (en) | 2001-06-11 | 2012-07-31 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
PT1401825E (en) | 2001-06-11 | 2009-10-23 | Virochem Pharma Inc | Thiophene derivatives as antiviral agents for flavivirus infection |
EP1321463B1 (en) | 2001-12-21 | 2007-08-08 | Virochem Pharma Inc. | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections |
HN2003000348A (en) * | 2002-11-01 | 2008-10-14 | Viropharma Inc | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND VIRAL INFECTION OF HEPATITIS C AND ASSOCIATED ILLNESSES. |
US7402608B2 (en) | 2002-12-10 | 2008-07-22 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
US20040192707A1 (en) | 2002-12-10 | 2004-09-30 | Laval Chan Chun Kong | Compounds and methods for the treatment or prevention of Flavivirus infections |
EP1569929B9 (en) | 2002-12-10 | 2011-09-14 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2005113548A1 (en) | 2004-05-20 | 2005-12-01 | Sugen, Inc. | Thiophene heteroaryl amines |
DE102004061746A1 (en) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkynyl-substituted thiophenes |
CA2607359C (en) | 2005-05-13 | 2011-08-09 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
JP2009520735A (en) | 2005-12-22 | 2009-05-28 | スミスクライン・ビーチャム・コーポレイション | Antiviral 2-carboxy-thiophene compound |
WO2008017688A1 (en) | 2006-08-11 | 2008-02-14 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti-viral agents |
TW200815384A (en) | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
WO2008043791A2 (en) | 2006-10-13 | 2008-04-17 | Smithkline Beecham Corporation | Thiophene derivatives for treating hepatitis c |
BRPI0718915A2 (en) | 2006-11-15 | 2013-12-03 | Virochem Pharma Inc | THIOPHEN ANALOGS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS |
EP2086966B1 (en) | 2006-11-17 | 2011-09-14 | GlaxoSmithKline LLC | 2-carboxy thiophene derivatives as anti viral agents |
GB0707092D0 (en) | 2007-04-12 | 2007-05-23 | Smithkline Beecham Corp | Compounds |
GB0712393D0 (en) | 2007-06-26 | 2007-08-01 | Smithkline Beecham Corp | Compounds |
GB0718435D0 (en) * | 2007-09-21 | 2007-10-31 | Northern Health And Social Car | Wpund care formulation |
EP2245023B1 (en) | 2008-02-14 | 2011-12-28 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
WO2009137500A1 (en) * | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
TW201136919A (en) * | 2010-03-02 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | Inhibitors of hepatitis C virus NS5B polymerase |
WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
US8324239B2 (en) * | 2010-04-21 | 2012-12-04 | Novartis Ag | Furopyridine compounds and uses thereof |
TW201221131A (en) * | 2010-11-18 | 2012-06-01 | Glaxo Group Ltd | Compounds |
US8771665B2 (en) | 2010-12-17 | 2014-07-08 | Cocrystal Discovery, Inc. | Inhibitors of hepatitis C virus polymerase |
US9707215B2 (en) | 2012-06-20 | 2017-07-18 | Cocrystal, Discovery, Inc. | Inhibitors of hepatitis C virus polymerase |
TWI731854B (en) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Inhibitors of hepatitis c virus polymerase |
-
2016
- 2016-03-21 TW TW105108618A patent/TWI731854B/en active
- 2016-03-23 CN CN201680017709.XA patent/CN107567442B/en active Active
- 2016-03-23 MX MX2017012238A patent/MX2017012238A/en unknown
- 2016-03-23 EA EA201792094A patent/EA033622B1/en not_active IP Right Cessation
- 2016-03-23 CA CA2979555A patent/CA2979555C/en active Active
- 2016-03-23 AU AU2016235246A patent/AU2016235246B2/en active Active
- 2016-03-23 KR KR1020177030184A patent/KR20170137113A/en active IP Right Grant
- 2016-03-23 EP EP16717211.3A patent/EP3274340B1/en active Active
- 2016-03-23 US US15/556,653 patent/US10464914B2/en active Active
- 2016-03-23 JP JP2018501147A patent/JP6741747B2/en active Active
- 2016-03-23 ES ES16717211T patent/ES2748974T3/en active Active
- 2016-03-23 PL PL16717211T patent/PL3274340T3/en unknown
- 2016-03-23 DK DK16717211.3T patent/DK3274340T3/en active
- 2016-03-23 SG SG11201707527YA patent/SG11201707527YA/en unknown
- 2016-03-23 WO PCT/US2016/023664 patent/WO2016154241A1/en active Application Filing
- 2016-03-23 NZ NZ735093A patent/NZ735093A/en unknown
-
2017
- 2017-08-31 IL IL254243A patent/IL254243B/en active IP Right Grant
- 2017-09-14 PH PH12017501687A patent/PH12017501687A1/en unknown
-
2018
- 2018-03-02 HK HK18103065.4A patent/HK1243703A1/en unknown
- 2018-07-13 HK HK18109115.1A patent/HK1249514A1/en unknown
-
2019
- 2019-09-25 US US16/582,468 patent/US10947210B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10464914B2 (en) | 2019-11-05 |
TWI731854B (en) | 2021-07-01 |
AU2016235246B2 (en) | 2020-12-10 |
MX2017012238A (en) | 2018-02-15 |
EP3274340A1 (en) | 2018-01-31 |
NZ735093A (en) | 2022-09-30 |
KR20170137113A (en) | 2017-12-12 |
WO2016154241A1 (en) | 2016-09-29 |
CN107567442A (en) | 2018-01-09 |
CA2979555C (en) | 2023-12-19 |
HK1249514A1 (en) | 2018-11-02 |
US20200255393A1 (en) | 2020-08-13 |
DK3274340T3 (en) | 2019-10-07 |
JP2018512453A (en) | 2018-05-17 |
EA201792094A1 (en) | 2018-03-30 |
CN107567442B (en) | 2021-05-25 |
HK1243703A1 (en) | 2018-07-20 |
IL254243A0 (en) | 2017-10-31 |
BR112017020168A2 (en) | 2018-06-05 |
PH12017501687A1 (en) | 2018-03-19 |
JP6741747B2 (en) | 2020-08-19 |
TW201643147A (en) | 2016-12-16 |
EP3274340B1 (en) | 2019-07-17 |
AU2016235246A1 (en) | 2017-09-21 |
EA033622B1 (en) | 2019-11-11 |
ES2748974T3 (en) | 2020-03-18 |
PL3274340T3 (en) | 2020-01-31 |
IL254243B (en) | 2020-10-29 |
US20180050998A1 (en) | 2018-02-22 |
CA2979555A1 (en) | 2016-09-29 |
US10947210B2 (en) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
HK1255502A1 (en) | Hepatitis b virus (hbv) irna compositions and methods of use thereof | |
IL251450A0 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
HK1243463A1 (en) | Compositions and methods for detecting an rna virus | |
HK1244913A1 (en) | Detection of genome editing | |
HK1248278A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
SG11201707663SA (en) | Lyophilization of rna | |
HK1231402A1 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections b d | |
SG10201913958QA (en) | Modulation of hepatitis b virus replication | |
HK1249046A1 (en) | Methods of treating hepatitis b virus | |
IL248318A0 (en) | Potent and selective inhibitors of hepatitis c virus | |
HK1249514A1 (en) | Inhibitors of hepatitis c virus polymerase | |
HUE044606T2 (en) | Treatment of hepatitis delta virus infection | |
GB201402169D0 (en) | Viral inhibitors | |
HK1231403A1 (en) | Nucleic acid capable of inhibiting expression of beta2gpi 2gpi | |
HK1245775A1 (en) | Salts as hepatitis c virus inhibitors | |
EP3445367A4 (en) | Hepatitis c virus inhibitors | |
GB201520019D0 (en) | The genome and self-evolution of AI | |
TH1601001227A (en) | HCV polymerase inhibitor | |
GB201416054D0 (en) | Chemotherapy of viruses |